Characterization and in vitro methotrexate release from methotrexate/gelatin conjugates of opposite conjugate bond polarity
- PMID: 11145239
- DOI: 10.1023/a:1026460023503
Characterization and in vitro methotrexate release from methotrexate/gelatin conjugates of opposite conjugate bond polarity
Abstract
Purpose: Our laboratory has previously prepared gelatin/ methotrexate (MTX) conjugates containing mixed conjugation sites and by-product crosslinking, both of which may alter conjugate effectiveness. In this study, we prepared and evaluated gelatin/MTX conjugates having specific conjugate bond sites and minimal by-product crosslinking.
Methods: Opposite polarity conjugates were produced by coupling gelatin having blocked amino groups with MTX (G-MTX) and by coupling MTX having blocked amino groups with gelatin (M-GEL) using 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide HCl. Amino groups were blocked using citraconic anhydride and deblocked under acidic conditions. Gelatin and MTX contents were determined spectrophotometrically. The stability of each conjugate was determined by evaluating their in vitro release of MTX in isotonic buffer at pH 7.4 and 37 degrees C for 7 days.
Results: The G-MTX and M-GEL conjugates contained 21 and 1.2 mole MTX/mole gelatin and released 12 and 17% MTX by 7 days resulting in pseudo-first order release rate constants of 0.76x10(-3) and 1.0x10(-3) hr(-1), respectively. Alternate MTX species (< or =10%) were detected during the release study and were attributed to low molecular weight gelatin/MTX fragments and MTX polymers.
Conclusions: Gelatin/MTX conjugates having opposite conjugate bond polarities and minimal by-product crosslinking have been produced and slowly released MTX by hydrolytic cleavage indicating good stability for future cell culture studies.
Similar articles
-
The effect of molecular weight, drug load, and charge of gelatin-MTX conjugates on growth inhibition of HL-60 leukemia cells.Pharm Res. 2009 Feb;26(2):338-45. doi: 10.1007/s11095-008-9746-5. Epub 2008 Oct 31. Pharm Res. 2009. PMID: 18975058
-
Characterization and in vitro release of methotrexate from gelatin/methotrexate conjugates formed using different preparation variables.Int J Pharm. 2000 Aug 25;204(1-2):81-9. doi: 10.1016/s0378-5173(00)00476-2. Int J Pharm. 2000. PMID: 11011989
-
Growth inhibition, drug load, and degradation studies of gelatin/methotrexate conjugates.Int J Pharm. 2006 Feb 3;308(1-2):90-9. doi: 10.1016/j.ijpharm.2005.10.037. Epub 2005 Dec 19. Int J Pharm. 2006. PMID: 16361072
-
Polyethylene glycol conjugates of methotrexate varying in their molecular weight from MW 750 to MW 40000: synthesis, characterization, and structure-activity relationships in vitro and in vivo.Bioconjug Chem. 2002 Jul-Aug;13(4):773-85. doi: 10.1021/bc010098m. Bioconjug Chem. 2002. PMID: 12121133
-
Gelatin-methotrexate conjugate microspheres as a potential drug delivery system.J Pharm Sci. 2006 Sep;95(9):1896-908. doi: 10.1002/jps.20572. J Pharm Sci. 2006. PMID: 16850436
Cited by
-
Carbodiimide induced cross-linking, ligand addition, and degradation in gelatin.Mol Pharm. 2015 Mar 2;12(3):783-93. doi: 10.1021/mp5006118. Epub 2015 Feb 6. Mol Pharm. 2015. PMID: 25658665 Free PMC article.
-
Preparation, drug release, and cell growth inhibition of a gelatin: doxorubicin conjugate.Pharm Res. 2013 Aug;30(8):2087-96. doi: 10.1007/s11095-013-1065-9. Epub 2013 May 18. Pharm Res. 2013. PMID: 23686374 Free PMC article.
-
Pharmacokinetics and Biodistribution of Pegylated Methotrexate after IV Administration to Mice.Iran J Pharm Res. 2018;17(Suppl2):111-123. Iran J Pharm Res. 2018. PMID: 31011346 Free PMC article.
-
The effect of molecular weight, drug load, and charge of gelatin-MTX conjugates on growth inhibition of HL-60 leukemia cells.Pharm Res. 2009 Feb;26(2):338-45. doi: 10.1007/s11095-008-9746-5. Epub 2008 Oct 31. Pharm Res. 2009. PMID: 18975058
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources